



Supplementary Figure 2. Comparison of responses to immune checkpoint inhibitors between patients with programmed death-ligand 1 (PD-L1) positivity in archival samples (pre-PD-L1 [+ group) and those with PD-L1 negativity in archival samples (pre-PD-L1 [- group). There were no significant differences in (A) progression-free survival (PFS) and (B) overall survival (OS) between the two groups. HR, hazard ratio; CI, confidence interval.